EirGenix, Inc. — Investor Relations & Filings

EirGenix, Inc. operates under a dual-engine business model, integrating Contract Development and Manufacturing Organization (CDMO) services with the development of proprietary biologics. The company provides comprehensive solutions spanning cell line development, process optimization, analytical testing, and cGMP-compliant manufacturing for both mammalian and microbial cultures. Its technical infrastructure includes large-scale production capabilities with multiple 2,000-liter single-use bioreactors and advanced continuous manufacturing platforms. EirGenix’s internal pipeline focuses on high-quality biosimilars, notably HER2-targeted therapies for breast cancer, including Trastuzumab biosimilar assets. Additionally, the company produces specialty products such as the CRM197 carrier protein and diagnostic tools. By leveraging integrated development and manufacturing expertise, EirGenix delivers cost-effective biopharmaceutical solutions to support global healthcare needs.